Polypeptide With Localisation/Targeting Motif TRIZ Cases

Identifies phosphorylated NPM to overcome insensitive traditional biomarkers, enabling earlier acute kidney injury diagnosis and targeted peptide therapy.

Segmenting the receptor into universal and modular units resolves the trade-off between tumor cell killing activity and off-target toxicity.

Mutating the Fc hinge prevents disulfide bonds, resolving steric hindrance that suppresses bioactivity in traditional two-chain fusion proteins.

Linking antigen binding to CD40 signaling enables universal donor B cells independent of MHC compatibility.

Engineered immune receptors incorporate synthetic co-stimulatory motifs to recruit intracellular signaling proteins for enhanced T cell activation.

A chimeric antigen receptor uses a protease cleavage site to release transcription factors upon antigen binding.

Engineered protein G variants with enhanced Fab domain affinity enable precise antibody purification and diagnostic assays.

Retro-inverso VDAC1 peptide analogues resist proteolytic degradation and improve solubility to maintain therapeutic efficacy against cancer.

Antibodies binding the E-cadherin linker block proteolytic shedding, resolving low treatment effectiveness in gastric cancer.

Antibody-peptide constructs cross the blood-brain barrier to target beta-amyloid oligomers.

Targeted BR1 and BR2 monoclonal antibodies recognize galactofuranose structures to reduce false positives in aspergillosis diagnosis.

Peptides block PBX-HOX protein interactions and maintain stem cell pluripotency despite limited cell penetration efficiency.

A chimeric protein vector uses the 48 to 96 amino acid ExoS N-terminal sequence to drive secretion and injection into eukaryotic cells.

Ribosome display links antibodies to RNA barcodes for parallel selection.

A trivalent bispecific antibody bridges tumor antigens and engineered T-cells to enable specific immune recruitment.

Replacing the extended cytoplasmic tail of HIV-1 Env with heterologous domains overcomes secretion restrictions and raises VLP incorporation levels.

A recombinant vector uses a fusion tag to increase target protein solubility and expression levels in host cells.

AcrIIA7 polypeptides inhibit Cas9 binding and cleavage, reducing off-target genome editing effects.

A mechanically interlocked complex links a Fab binding moiety to a steric hindering chemical group through a linker passing through the Fab domain hole.

Segmenting the CD45 antigen into the CD45RA isoform allows Mu3A4-CAR-T cells to destroy target cells while sparing normal hematopoietic stem cells.

LRRC24 penetrating domain delivers SARS-CoV-2 antigen into immune cells, resolving low potency and insufficient neutralizing antibody production.

Segmented Cas9 nickase and deaminase components eliminate random off-target mutations while preserving precise genome editing specificity.

Targeting Glypican 3 with anti-GPC3 agents addresses high relapse rates in myxoid liposarcoma patients through precise biomarker-guided selection.

Secreted soluble scFv blocks HLA-G immune checkpoints in the tumor microenvironment, restoring T cell activity against resistant cancers.

Single 4G5 antibody replaces species-specific reagents by targeting conserved FAP regions to simplify preclinical modeling and therapy.

Fusing pre-region and pro-region sequences creates signal peptides that prevent cytosolic aggregation during protein synthesis.

Analyzing urine for glycan tumour antigens using capillary gel electrophoresis and laser-induced fluorescence.

Autologous feeder culture expands gamma delta T cells up to 100-fold without irradiation, bypassing graft-versus-host disease risks.

Engineered synthetic receptors use fibronectin repeats to trigger ligand-dependent transcriptional regulation without bulky regulatory regions.

Combines GDF traps with erythropoietin receptor activators to synergistically increase red blood cell formation while reducing adverse effects.

Histidine-lysine polypeptides form nanoparticles to protect siRNA from serum nucleases, enabling targeted tumor delivery.

Kindlin-1 binding peptides inhibit beta-integrin activation, reducing breast cancer cell proliferation and metastasis.

Proximity-dependent biotin identification tags proteins in the endoplasmic reticulum lumen, enabling precise tissue origin identification of plasma secretomes.

Bispecific ACE2 anti-CD3 molecules redirect T cell cytotoxicity toward infected cells, maintaining efficacy against evolving viral mutations.

Preliminary gene introduction establishes endogenous enzyme production, resolving compliance issues from frequent administration.

Protease-sensitive linkers mask CAR T recognition domains, preventing off-target effects while enabling specific tumor targeting.

Chimeric antigen receptors integrate CD28 and 4-1BB domains to sustain T cell activity against tumors.

Soluble ENPP1 polypeptides hydrolyze phosphodiester bonds to prevent kidney stones, addressing poor patient tolerance of conventional phosphate supplements.

Native signal peptides direct protein secretion in Picochlorum renovo, eliminating intracellular recovery costs and reducing carbon source reliance.

Pairing inhibitory and activating chimeric antigen receptors prevents off-tumor toxicity while maintaining effective cancer cell elimination.

Modified M13 phage linkers allow identification of cell-penetrating peptides with improved cytosolic uptake while avoiding lysosomal degradation.

Engineering MALT1 protease for constitutive activity prevents T cell exhaustion and maintains anti-tumor efficacy.

A regulatable destabilization domain controls chimeric antigen receptor surface levels through ligand-mediated protein stability.

Engineered T4 phage capsids package DNA while displaying fusion proteins on their surface.

A recombinant Frataxin fusion protein uses a mitochondrial membrane-penetrating peptide to localize therapeutic activity within the mitochondrial matrix.

Segmented sgRNA blocks Cas9 activation to resolve the efficiency versus specificity trade-off in genome editing.

Viral vectors deliver patient-specific neoepitopes with co-stimulatory molecules, overcoming weak immune responses from generic tumor antigens.

Segmenting patients by FGFR3 fusion status localizes inhibitor treatment to responders, reducing side effects from ineffective generic dosing.

CAR-T membrane coated nanoparticles use native ligands to target cancer cells, reducing systemic toxicity and improving delivery efficiency.